Search
Benchtalk 2025: Kate Haviland discusses the $9B+ acquisition of Blueprint by Sanofi, being chair of Fulcrum, her thoughts on M&A, and what is interesting in biotech today
The CEO of Blueprint (up to the acquisition) discusses the company's success factors, and being led to immunology by the science. Plus, why she believes an oral pill that is disease modifying, like Fulcrum is trying to develop, is strongly needed for the sickle cell patient community. Coverage brought to you by
2 hours ago
Benchtalk 2025: Benchling Co-Founder & CEO Sajith Wickramasekara describes why he believes science and Benchling are entering a new era of speed and cost of R&D
He welcomes us to Benchtalk 2025, which had more than 800 scientists register this year, and describes how AI and other computational advances are allowing scientists to focus on increasing the speed and reducing the cost of R&D. Coverage brought to you by
8 hours ago
Savills has published a new report - U.S. Life Sciences State of the Market 2025
We spoke with Brianna Friedman from the research team to go behind the numbers and learn how today's environment for life sciences is...
5 days ago
NYSE Market Strategist Eric Criscuolo discusses biotech's newfound momentum and whether it might attract generalists to take a look at the sector
He discusses the rally biotech has had of late, and that was boosted by Pfizer's deal with the White House. Plus, how interest rates,...
6 days ago
R.W. Baird Managing Director & Senior Biotech Analyst Brian Skorney discusses numerous battleground companies in biotech
He shares his thoughts on Soleno, Sarepta, Lexeo, Enanta, Crinetics, Vertex, Xenon, and more. Chapters General Biotech Sentiment - 1:02...
6 days ago
Sunny Kumar, a partner at Informed Ventures, and an active investor in the AI space, talks about current and future implications of AI's impact on healthcare
He discussed how current technologies are making healthcare more effecient today, how new technologies are opening new markets, and how...
Sep 26
Pareto Securities' Healthcare Conference: Biotech Analyst Dan Akschuti shares his take on the the conference and the state of biotech, and highlights key companies to watch in the region
He sees an optimistic turn after a challenging couple of years. Plus, highlighting Vicore, Camurus, Oculis, and BioArctic. Coverage...
Sep 16
Leaders of Brandon Capital, a seed and VC firm formed in Australia and with an office in the UK as well, discuss their $290 million sixth fund
Founding Partner Stephen Thompson and Partner Jonathan Tobin list some of their recent investments, highlight the advantage of running...
Sep 12
Michael White, Head of Life Sciences & Healthcare, UK & Nordics at HSBC Innovation Banking, shares insights from his team's UK & Nordics: Life Sciences & Healthcare 1H 2025 Venture Financing Report
The report is full of data that shows where venture money is being invested in the region and by which investors, and includes these...
Sep 11
H.C. Wainwright & Co. CEO Mark Kaplan sees a warming up of the fundraising environment for biotech over the coming months
Kicking off BiotechTV's coverage of the 2025 HCW Global Investor Conference in New York, the new CEO of H.C. Wainwright gives his take on...
Sep 8
Stanford professor James Zou and his team created a virtual lab with AI scientists - they designed nanobodies for a COVID variant
Dr. Zou describes this work, which was published recently in Nature, and how the the AI scientists were able to do everything from debate...
Aug 26
William Blair Senior Biotech Analyst Andy Hsieh reacts to today's oral obesity data from Viking's VK2735 and recent data from Lilly's orforglipron
He shares his take on today's data, which saw Viking's stock decline by over 40%, and Lilly's earlier data which also sparked a Wall...
Aug 19
AI News: While most AI in healthcare is aimed at helping physicians better diagnose and treat disease, CureWise is built for patients to help understand their conditions and ask the right questions
Founder & CEO Steve Brown, who created CureWise after receiving his own diagnosis of a rare blood cancer, describes his journey and how...
Aug 7
As independent tenant advocates, Savills can help biotech and pharma companies make their real estate footprint align with their objectives and be more efficient
Austin Barrett, Vice Chairman and Head of Life Sciences, describes the type of work Savills does for clients today, including...
Jul 30
NYSE Strategist Eric Criscuolo shares his take on the markets and biotech sentiment
He discusses the importance of interest rates to high risk sectors like biotech, and comment on how our sector has not performed lately...
Jul 22
RBC's Healthcare Desk Strategist Chris McCarthy discusses biotech sentiment, and positioning around key events and catalysts that are upcoming
He highlights recent M&A, but also notes how the sector has not been reliant on deals like it has in the past. Plus, discussing how...
Jul 22
Jon Norris shares highlights from his 2025 Mid-Year Venture Healthcare Report
He discusses trends in deal size, therapeutic focus, IPOs, and more. DOWNLOAD THE FULL REPORT #sponsored
Jul 21
Southampton professor, and Curve Therapeutics' CSO, Ali Tavassoli describes the unique properties of cyclic peptides and why he believes Curve's cell-based method to drug discovery makes it different
He describes the properties that make cyclic peptides unique compared to small molecules and antibodies, and how Curve's approach is...
Jul 15
Jones Research analyst Catherine Novack discusses Capricor's regulatory roller coaster, RNA editing, and more
She gives a scenario analysis in the event that FDA asked Capricor for more data rather than approving the therapy by its August 31st...
Jun 27
Discussing hot button issues for biotech, and how they do or don't affect the mechanics of M&A, with one of the most experienced bankers in healthcare, Jefferies' Philip Ross
He describes how some front and center issues for biotech either do or don't affect the M&A environment such as China, negative enterprise values, the FTC, valuations, the patent cliff, and more.
Jun 27
.png){kind=logo}
